financetom
Business
financetom
/
Business
/
Aurora Innovation Insider Sold Shares Worth $27,455,944, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aurora Innovation Insider Sold Shares Worth $27,455,944, According to a Recent SEC Filing
Nov 9, 2024 1:35 PM

05:25 PM EST, 11/08/2024 (MT Newswires) -- Reid Hoffman, Director, on November 06, 2024, sold 4,929,713 shares in Aurora Innovation ( AUR ) for $27,455,944. Following the Form 4 filing with the SEC, Hoffman has control over a total of 9,154,991 shares of the company, with 286,247 shares held directly and 8,868,744 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1828108/000182810824000145/xslF345X05/wk-form4_1731103992.xml

Price: 5.19, Change: +0.01, Percent Change: +0.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Caleres Keeps Regular Quarterly Cash Dividend at $0.07 a Share, Payable April 12 to Holders of Record March 28
--Caleres Keeps Regular Quarterly Cash Dividend at $0.07 a Share, Payable April 12 to Holders of Record March 28
Mar 14, 2024
05:38 PM EDT, 03/14/2024 (MT Newswires) -- Price: 38.5, Change: +0.16, Percent Change: +0.42 ...
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment
Mar 14, 2024
05:38 PM EDT, 03/14/2024 (MT Newswires) -- Nuvation Bio ( NUVB ) said late Thursday the first patient has been dosed in a phase 1/2 study of NUV-1511 to treat advanced solid tumors. The company said the study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for indications of clinical activity in patients with advanced solid tumors who...
Madrigal Pharmaceuticals Gets FDA Approval for Liver Fibrosis Therapy
Madrigal Pharmaceuticals Gets FDA Approval for Liver Fibrosis Therapy
Mar 14, 2024
05:36 PM EDT, 03/14/2024 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) received the US Food and Drug Administration's accelerated approval of Rezdiffra for treating adults with noncirrhotic nonalcoholic steatohepatitis and moderate to advanced liver fibrosis, the company said Thursday. Rezdiffra, which is a once-daily oral therapy, was approved in combination with diet and exercise, the company said. The approval...
Getty Images Stock Climbs On Better-Than-Expected Q4 Revenue Results
Getty Images Stock Climbs On Better-Than-Expected Q4 Revenue Results
Mar 14, 2024
Getty Images Holdings Inc. ( GETY ) reported its fourth-quarter financial results after the bell Thursday. Here's a look at the details.  The Details: The company reported quarterly sales of $225.94 million which beat the analyst consensus estimate of $216.46 million by 4.38% and is a 2.39% decrease over sales of $231.47 million from the same period last year. Getty...
Copyright 2023-2026 - www.financetom.com All Rights Reserved